Ong A.C. Devuyst O. Knebelmann B. Walz G.

Autosomal dominant polycystic kidney disease: the changing face of clinical management.

Lancet (London, England). 385: 1993-2002https://doi.org/10.1016/s0140-6736(15)60907-2Spithoven E.M. Kramer A. Meijer E. et al.

Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 29: iv15-25https://doi.org/10.1093/ndt/gfu017Chapman A.B. Devuyst O. Eckardt K.U. et al.

Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Kidney international. 88: 17-27https://doi.org/10.1038/ki.2015.59

Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease.

Clinical Journal of the American Society of Nephrology. 13: 1765https://doi.org/10.2215/CJN.03960318Torres V.E. Harris P.C. Pirson Y.

Autosomal dominant polycystic kidney disease.

Lancet (London, England). 369: 1287-1301https://doi.org/10.1016/s0140-6736(07)60601-1Tong A. Tunnicliffe D.J. Lopez-Vargas P. et al.

Identifying and integrating consumer perspectives in clinical practice guidelines on autosomal-dominant polycystic kidney disease.

Nephrology (Carlton). Feb. 21: 122-132https://doi.org/10.1111/nep.12579Sautenet B. Cho Y. Gutman T. et al.

Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review.

American journal of kidney diseases : the official journal of the National Kidney Foundation. 76: 213-223https://doi.org/10.1053/j.ajkd.2019.12.003Tong A. Rangan G.K. Ruospo M. et al.

A painful inheritance-patient perspectives on living with polycystic kidney disease: thematic synthesis of qualitative research.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 30: 790-800https://doi.org/10.1093/ndt/gfv010Tong A. Craig J.C. Nagler E.V. Van Biesen W.

Composing a new song for trials: the Standardized Outcomes in Nephrology (SONG) initiative.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 32: 1963-1966https://doi.org/10.1093/ndt/gfx288Cho Y. Sautenet B. Rangan G. et al.

Standardised Outcomes in Nephrology—Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease.

Trials. 2017/11/23. 18: 560https://doi.org/10.1186/s13063-017-2298-4Liberati A. Altman D.G. Tetzlaff J. et al.

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.

BMJ. 339: b2700https://doi.org/10.1136/bmj.b2700Dijk M. Breuning M. Duiser R. Es L. Westendorp R.

No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrology, dialysis, transplantation. Clinical Trial; Randomized Controlled Trial.

Research Support, Non-U.S. Gov't. 18: 2314-2320Ruggenenti P. Gentile G. Perico N. et al.

Effect of sirolimus on disease progression in patients with autosomal dominant polycystic kidney disease and CKD stages 3b-4.

Clinical journal of the american society of nephrology. Article. 11: 785-794https://doi.org/10.2215/CJN.09900915Ruggenenti P. Remuzzi A. Ondei P. et al.

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease.

Kidney international. Clinical Trial; Randomized Controlled Trial. 68: 206-216https://doi.org/10.1111/j.1523-1755.2005.00395.xBoertien W.E. Meijer E. de Jong P.E. et al.

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.

Kidney international. 84: 1278-1286https://doi.org/10.1038/ki.2013.285Schrier R. McFann K. Johnson A. et al.

Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study.

Journal of the american society of nephrology : JASN. Clinical Trial; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 13: 1733-1739Ecder T. Chapman A. Brosnahan G. Edelstein C. Johnson A. Schrier R.

Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.

American journal of kidney diseases. Clinical Trial; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. 35: 427-432Chapman A.B. Johnson A. Gabow P.A. Schrier R.W.

The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.

The New England journal of medicine. 323: 1091-1096https://doi.org/10.1056/nejm199010183231602Barrett B. Foley R. Morgan J. Hefferton D. Parfrey P.

Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney international. Clinical Trial; Controlled Clinical Trial.

Research Support, Non-U.S. Gov't. 46: 1118-1123Al T.S. Malmberg M. Rosenbaek J. Bech J. Pedersen E.

Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.

BMC nephrology. Article. 18 https://doi.org/10.1186/s12882-017-0686-3Doulton T. Saggar-Malik A. He F. et al.

The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients.

Journal of hypertension. Comparative Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't. 24: 939-945https://doi.org/10.1097/01.hjh.0000222765.30348.0dPerico N. Ruggenenti P. Perna A. et al.

Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.

PLoS medicine. 16e1002777https://doi.org/10.1371/journal.pmed.1002777Spinelli L. Pisani A. Giugliano G. et al.

Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial.

International journal of cardiology. 275: 145-151https://doi.org/10.1016/j.ijcard.2018.10.063El-Damanawi R. Lee M. Harris T. et al.

High water vs. ad libitum water intake for autosomal dominant polycystic kidney disease: a randomized controlled feasibility trial.

Qjm. Apr. 113: 258-265https://doi.org/10.1093/qjmed/hcz278Serra A. Kistler A. Poster D. et al.

Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease. Nephrology, dialysis, transplantation. Randomized Controlled Trial.

Research Support, Non-U.S. Gov't. 24: 3334-3342https://doi.org/10.1093/ndt/gfp280King B.F. Torres V.E. Brummer M.E. et al.

Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.

Kidney international. 64: 2214-2221https://doi.org/10.1046/j.1523-1755.2003.00326.xBardají A. Martinez-Vea A. Valero A. et al.

Cardiac involvement in autosomal-dominant polycystic kidney disease: a hypertensive heart disease.

Clin Nephrol. Sep. 56: 211-220Chapman A.B. Johnson A.M. Gabow P.A. Schrier R.W.

Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease.

J Am Soc Nephrol. Dec. 5: 1349-1354Gansevoort R. Meijer E. Chapman A. et al.

Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3: 4 Trial. Nephrology dialysis transplantation.

Journal: Article. 31: 1887-1894https://doi.org/10.1093/ndt/gfv422Chapman A.B. Johnson A.M. Rainguet S. Hossack K. Gabow P. Schrier R.W.

Left ventricular hypertrophy in autosomal dominant polycystic kidney disease.

J Am Soc Nephrol. Aug. 8: 1292-1297Walz G. Budde K. Mannaa M. et al.

Everolimus in patients with autosomal dominant polycystic kidney disease.

New England journal of medicine. Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't. 363: 830-840https://doi.org/10.1056/NEJMoa1003491Cadnapaphornchai M. McFann K. Strain J. Masoumi A. Schrier R.

Prospective change in renal volume and function in children with ADPKD.

Clinical journal of the American Society of Nephrology. Comparative Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't. 4: 820-829https://doi.org/10.2215/CJN.02810608Torres V.E. King B.F. Chapman A.B. et al.

Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.

Clinical journal of the American Society of Nephrology : CJASN. Jan. 2: 112-120https://doi.org/10.2215/cjn.00910306Torres V.E. Grantham J.J. Chapman A.B. et al.

Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.

Clinical journal of the American Society of Nephrology : CJASN. Mar. 6: 640-647https://doi.org/10.2215/cjn.03250410Ulusoy S. Ozkan G. Orem C. Kaynar K. Ko?ucu P. Kiri A.

A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease. Renal failure. Comparative Study.

Randomized Controlled Trial. 32: 913-917https://doi.org/10.3109/0886022X.2010.502277Cadnapaphornchai M. George D. McFann K. et al.

Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.

Clinical journal of the American Society of Nephrology. Clinical Trial, Phase III; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't. 9: 889-896https://doi.org/10.2215/CJN.08350813Schrier R. Abebe K. Perrone R. et al.

Blood pressure in early autosomal dominant polycystic kidney disease.

New England journal of medicine. Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't. 371: 2255-2266https://doi.org/10.1056/NEJMoa1402685Torres V.E. Abebe K.Z. Chapman A.B. et al.

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

The New England journal of medicine. 371: 2267-2276https://doi.org/10.1056/NEJMoa1402686Fick-Brosnahan G.M. Belz M.M. McFann K.K. Johnson A.M. Schrier R.W.

Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study.

American journal of kidney diseases : the official journal of the National Kidney Foundation. 39: 1127-1134https://doi.org/10.1053/ajkd.2002.33379Dad T. Abebe K.Z. Bae K.T. et al.

Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.

Kidney international reports. 3: 619-624https://doi.org/10.1016/j.ekir.2017.12.011Boertien W.E. Meijer E. Li J. et al.

Relationship of Copeptin, a Surrogate Marker for Arginine Vasopressin, With Change in Total Kidney Volume and GFR Decline in Autosomal Dominant Polycystic Kidney Disease: Results From the CRISP Cohort.

American Journal of Kidney Diseases. 61: 420-429https://doi.org/10.1053/j.ajkd.2012.08.038Fassett R. Coombes J. Packham D. Fairley K. Kincaid-Smith P.

Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease.

Scandinavian journal of urology and nephrology. Randomized Controlled Trial; Research Support, Non-U.S. Gov't. 44: 56-61https://doi.org/10.3109/00365590903359908Gabow P.A. Chapman A.B. Johnson A.M. et al.

Renal structure and hypertension in autosomal dominant polycystic kidney disease.

Kidney international. 38: 1177-1180https://doi.org/10.1038/ki.1990.330

Klahr S, Breyer J, Beck G, et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. Journal of the american society of nephrology : JASN. Clinical Trial; Comparative Study; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. 1995;5(12):2037-2047.

Shamshirsaz A.A. Reza Bekheirnia M. Kamgar M. et al.

Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome.

Kidney international. 68: 2218-2224https://doi.org/10.1111/j.1523-1755.2005.00678.xStallone G. Infante B. Grandaliano G. et al.

Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.

Nephrology, dialysis, transplantation. Randomized Controlled Trial; Research Support, Non-U.S. Gov't. 27: 3560-3567https://doi.org/10.1093/ndt/gfs264Meijer E. Rook M. Tent H. et al.

Early renal abnormalities in autosomal dominant polycystic kidney disease.

Clinical journal of the American Society of Nephrology : CJASN. Jun. 5: 1091-1098https://doi.org/10.2215/cjn.00360110Fick-Brosnahan G.M. Tran Z.V. Johnson A.M. Strain J.D. Gabow P.A.

Progression of autosomal-dominant polycystic kidney disease in children.

Kidney international. 59: 1654-1662https://doi.org/10.1046/j.1523-1755.2001.0590051654.xSharp C. Johnson A. Gabow P.

Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease.

J Am Soc Nephrol. Oct. 9: 1908-1914Zeltner R. Poliak R. Stiasny B. Schmieder R. Schulze B.

Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.

Nephrology, dialysis, transplantation. Comparative Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't. 23: 573-579https://doi.org/10.1093/ndt/gfm731Kocyigit I. Yilmaz M.I. Orscelik O. et al.

Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease.

Nephron Clinical practice. 123: 157-164https://doi.org/10.1159/000353730Kocyigit I. Ozturk F. Eroglu E. et al.

Dysmetabolic markers predict outcomes in autosomal dominant polycystic kidney disease.

Clinical and experimental nephrology. 23: 1130-1140https://doi.org/10.1007/s10157-019-01748-zMassella L. Mekahli D. Paripović D. et al.

Prevalence of Hypertension in Children with Early-Stage ADPKD.

Clinical journal of the American Society of Nephrology : CJASN. 13: 874-883https://doi.org/10.2215/cjn.11401017Ivy D.D. Shaffer E.M. Johnson A.M. Kimberling W.J. Dobin A. Gabow P.A.

Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease.

J Am Soc Nephrol. Jun. 5: 2032-2036Ecder T. Edelstein C. Chapman A. et al.

Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.

Nephrology, dialysis, transplantation. Clinical Trial; Randomized Controlled Trial. 14: 1113-1116Nakamura T. Sugaya T. Kawagoe Y. Ueda Y. Osada S. Koide H.

Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.

American journal of the medical sciences. Clinical Trial; Randomized Controlled Trial. 330: 161-165Caroli A. Perico N. Perna A. et al.

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.

Lancet (London, England). 382: 1485-1495https://doi.org/10.1016/s0140-6736(13)61407-5Soliman A. Zamil S. Lotfy A. Ismail E.

Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment.

Transplantation proceedings. Randomized Controlled Trial. 44: 2936-2939https://doi.org/10.1016/j.transproceed.2012.06.073Nakamura T. Ushiyama C. Takahashi Y. et al.

Effect of dilazep dihydrochloride on urinary album in excretion in patients with autosomal dominant polycystic kidney disease.

Nephron. Journal: Article. 88: 80-82https://doi.org/10.1159/000045963Nakamura T. Sato E. Fujiwara N. et al.

Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension.

American journal of the medical sciences. Journal: Article. 343: 46-51https://doi.org/10.1097/MAJ.0b013e31821f0552Taylor J. Hamilton-Reeves J. Sullivan D. et al.

Diet and polycystic kidney disease: a pilot intervention study.

Clinical nutrition (edinburgh, scotland). Article. 36: 458-466https://doi.org/10.1016/j.clnu.2016.01.003Lumiaho A. Pihlajamäki J. Hartikainen J. et al.

Insulin resistance is related to left ventricular hypertrophy in patients with polycystic kidney disease type 1.

American journal of kidney diseases : the official journal of the National Kidney Foundation. 41: 1219-1224https://doi.org/10.1016/s0272-6386(03)00354-8Hogan M.C. Abebe K. Torres V.E. et al.

Liver involvement in early autosomal-dominant polycystic kidney disease.

Clin Gastroenterol Hepatol. Jan. 13: 155-164.e6https://doi.org/10.1016/j.cgh.2014.07.051Chen D. Ma Y. Wang X. et al.

Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease.

PLoS One. 9e92232https://doi.org/10.1371/journal.pone.0092232Irazabal M.V. Torres V.E. Hogan M.C. et al.

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

Kidney international. 80: 295-301https://doi.org/10.1038/ki.2011.119Torres V. Chapman A. Devuyst O. et al.

Tolvaptan in patients with autosomal dominant polycystic kidney disease.

New England journal of medicine. Clinical Trial, Phase III; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't. 367: 2407-2418https://doi.org/10.1056/NEJMoa1205511Ozkok A. Akpinar T.S. Tufan F. et al.

Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience.

Clinical and experimental nephrology. Jun. 17: 345-351https://doi.org/10.1007/s10157-012-0706-3Schrier R.W. Johnson A.M. McFann K. Chapman A.B.

The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease.

Kidney international. Nov. 64: 1792-1799https://doi.org/10.1046/j.1523-1755.2003.00264.xSchrier R.W. McFann K.K. Johnson A.M.

Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney international.

Feb. 63: 678-685https://doi.org/10.1046/j.1523-1755.2003.00776.xChoukroun G. Itakura Y. Albouze G. et al.

Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease.

J Am Soc Nephrol. Dec. 6: 1634-1642Nowak K.L. Gitomer B. Farmer-Bailey H. et al.

Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.

American journal of kidney diseases : the official journal of the National Kidney Foundation. 74: 213-223https://doi.org/10.1053/j.ajkd.2018.12.037Rizk D. Jurkovitz C. Veledar E. et al.

Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis.

Clinical journal of the American Society of Nephrology : CJASN. 4: 560-566https://doi.org/10.2215/CJN.02410508Nicolau C. Torra R. Bianchi L. et al.

Abdominal sonographic study of autosomal dominant polycystic kidney disease.

J Clin Ultrasound. 28: 277-282https://doi.org/10.1002/1097-0096(200007/08)28:6<277::aid-jcu2>3.0.co;2-lGabow P.A. Johnson A.M. Kaehny W.D. et al.

Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease.

Kidney international. 41: 1311-1319https://doi.org/10.1038/ki.1992.195Torres V.E. Higashihara E. Devuyst O. et al.

Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

Clinical journal of the American Society of Nephrology : CJASN. 11: 803-811https://doi.org/10.2215/cjn.06300615Muto S. Kawano H. Higashihara E. et al.

The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3: 4 trial. Clinical and experimental nephrology.

Journal: Article. 19: 867-877https://doi.org/10.1007/s10157-015-1086-2Devuyst O. Chapman A. Gansevoort R. et al.

Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: results from the TEMPO 3: 4 Trial.

Journal of the american society of nephrology : JASN. Clinical Trial, Phase III; Multicenter Study; Randomized Controlled Trial. 28: 1592-1602https://doi.org/10.1681/ASN.2016040448Irazabal M.V. Blais J.D. Perrone R.D. et al.

Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3: 4 Clinical Trial.

Kidney international reports. 1: 213-220https://doi.org/10.1016/j.ekir.2016.08.001Nowak K.L. Cadnapaphornchai M.A. Chonchol M.B. Schrier R.W. Gitomer B.

Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.

Am J Nephrol. 44: 171-178https://doi.org/10.1159/000448695Tesar V. Ciechanowski K. Pei Y. et al.

Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.

Journal of the american society of nephrology : JASN. Clinical Trial, Phase II; Multicenter Study; Randomized Controlled Trial. 28: 3404-3413https://doi.org/10.1681/ASN.2016111232Nowak K.L. Chonchol M. You Z. Gupta M. Gitomer B.

Affected parent sex and severity of autosomal dominant polycystic kidney disease: a retrospective cohort study.

Clin Nephrol. Mar. 89: 196-204https://doi.org/10.5414/cn109247Reed B. Helal I. McFann K. Wang W. Yan X.D. Schrier R.W.

The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 27: 2862-2865https://doi.org/10.1093/ndt/gfr744Helal I. McFann K. Reed B. Yan X.D. Schrier R.W. Fick-Brosnahan G.M.

Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 28: 380-385https://doi.org/10.1093/ndt/gfs417Dijk M. Kamper A. Veen S. Souverijn J. Blauw G.

Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease.

Nephrology, dialysis, transplantation. Clinical Trial; Randomized Controlled Trial. 16: 2152-2157Florijn K. Barendregt J. Lentjes E. et al.

Glomerular filtration rate measurement by "single-shot" injection of inulin.

Kidney international. Clinical Trial; Comparative Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't. 46: 252-259Yamaguchi T. Higashihara E. Okegawa T. Miyazaki I. Nutahara K.

Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan.

Clinical and experimental nephrology. 22: 1213-1223https://doi.org/10.1007/s10157-018-1574-2Perico N. Antiga L. Caroli A. et al.

Sirolimus therapy to halt the progression of ADPKD.

Journal of the american society of nephrology : JASN. Randomized Controlled Trial. 21: 1031-1040https://doi.org/10.1681/ASN.2009121302Hogan M. Masyuk T. Page L. et al.

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

Journal of the american society of nephrology : JASN. Randomized Controlled Trial. 21: 1052-1061https://doi.org/10.1681/ASN.2009121291Hogan M. Masyuk T. Bergstralh E. et al.

Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease. Mayo clinic proceedings. Randomized Controlled Trial.

Research Support, Non-U.S. Gov't. 90: 1030-1037https://doi.org/10.1016/j.mayocp.2015.05.011Grantham J.J. Torres V.E. Chapman A.B. et al.

Volume Progression in Polycystic Kidney Disease.